CalciMedica is trading 5.56% up in pre-market at $1.71 on October 5, with no clear company-specific catalyst identified.

  • The October 2 close was $1.60.
  • A September 30 prospectus supplement enables up to $25 million in stock sales through an existing at-the-market program. It is relevant financing context, but available evidence does not establish that it caused the gain.
  • Major indices are modestly lower, so broader-market strength does not clearly explain the move either.